Kymera Therapeutics (KYMR) Total Liabilities (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Total Liabilities data on file, last reported at $129.4 million in Q1 2026.

• On a quarterly basis, Total Liabilities fell 2.04% year-over-year to $129.4 million in Q1 2026; TTM through Mar 2026 was $129.4 million, a 2.04% decrease from a year earlier, with the FY2025 full-year figure at $163.1 million, up 14.56% from the prior year.
• Total Liabilities for Q1 2026 stood at $129.4 million, down from $163.1 million in the prior quarter.
• Over the last five years, Total Liabilities for KYMR reached as high as $180.8 million in Q4 2023 and fell as low as $113.0 million in Q4 2022.
• Historically, Total Liabilities has averaged $144.5 million across 5 years, with a median of $142.4 million in 2024.
• Across the five-year window, Total Liabilities decreased 29.04% in 2022 and jumped 60.01% in 2023, its largest moves.
• Year by year, Total Liabilities stood at $113.0 million in 2022, then soared by 60.01% to $180.8 million in 2023, then fell by 21.22% to $142.4 million in 2024, then grew by 14.56% to $163.1 million in 2025, then declined by 20.7% to $129.4 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $129.4 million in Q1 2026, $163.1 million in Q4 2025, and $155.8 million in Q3 2025.